HA/HSA co-modified erlotinib&amp;ndash;albumin nanoparticles for lung cancer treatment

Shen, Yi; Li, Wentao

doi:10.2147/dddt.s169734

Cited by 61 publications

(22 citation statements)

References 29 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-based nanoparticles have been used to deliver erlotinib [ 48 ] and afatinib [ 49 ] and are shown to have enhanced therapeutic efficacy against NSCLC. Similarly, hyaluronic acid-based nanoparticles have been explored for the delivery of erlotinib [ 50 ] and afatinib [ 51 ] to target tumors.…”

Section: Targeting Egfr and Vegfr With Different Inhibition Modalimentioning

confidence: 99%

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

et al. 2021

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers. As a result, these receptor families constitute attractive targets for imaging and therapeutic applications in the detection and treatment of cancer. This review explores the dynamic structure and structure-function relationships of these two growth factor receptors and their significance as it relates to theranostics of cancer, followed by some of the common inhibition modalities frequently employed to target EGFR and VEGFR, such as tyrosine kinase inhibitors (TKIs), antibodies, nanobodies, and peptides. A summary of the recent advances in molecular imaging techniques, including positron emission tomography (PET), single-photon emission computerized tomography (SPECT), computed tomography (CT), magnetic resonance imaging (MRI), and optical imaging (OI), and in particular, near-IR fluorescence imaging using tetrapyrrolic-based fluorophores, concludes this review.

show abstract

Section: Targeting Egfr and Vegfr With Different Inhibition Modalimentioning

confidence: 99%

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This protein improves the release of drug bioavailability and decreases drug resistance in the body [ 29 ]. It is non-toxic and non-immunogenic [ 30 ]. Albumin-bound technology (named nab-technology) was developed and used for the delivery of drugs in the treatment of various types of tumors [ 31 ].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?

et al. 2021

View full text Add to dashboard Cite

This review aims to provide the state of the art on polymeric and lipid nanoparticles, used or suggested to approach pediatric diseases’ problems and needs, and to inspire new researches in this field. Several drugs are currently not available in formulations suitable for pediatric patients. The United States Pediatric Formulation Initiative suggested applying new technologies to pediatric drug formulations, for instance, nanotechnology. The literature analysis showed that polymeric and lipid nanoparticles have been widely studied to treat pediatric diseases, and albumin nanoparticles and liposomes are already used in clinical practice. Nevertheless, these studies are focused almost exclusively on pediatric cancer treatment. Although nanomedicine may solve many needs of pediatric diseases and medicines, the unavailability of data on pharmacokinetics, safety and efficacy of both drugs and nanoparticles in pediatric patients limits the development of new pediatric medicines based on nanoparticles. Therefore, nanomedicine applied in pediatrics remains a significant challenge in the near future.

show abstract

“…The pharmacokinetic parameters (blood residence time) in vivo of HA-decorated NPs were similar to that of ERT-HSA NPs. However, in terms of in vivo antitumor activity, mice treated with ERT-HSA-HA NPs showed a significantly suppressed tumor growth and no relapse after 30 days of treatment [ 173 ].…”

Section: Reviewmentioning

confidence: 99%

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

Geškovski¹,

Matevska-Geshkovska²,

Sazdovska³

et al. 2021

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Nanomedicine has emerged as a novel cancer treatment and diagnostic modality, whose design constantly evolves towards increasing the safety and efficacy of the chemotherapeutic and diagnostic protocols. Molecular diagnostics, which create a great amount of data related to the unique molecular signatures of each tumor subtype, have emerged as an important tool for detailed profiling of tumors. They provide an opportunity to develop targeting agents for early detection and diagnosis, and to select the most effective combinatorial treatment options. Alongside, the design of the nanoscale carriers needs to cope with novel trends of molecular screening. Also, multiple targeting ligands needed for robust and specific interactions with the targeted cell populations have to be introduced, which should result in substantial improvements in safety and efficacy of the cancer treatment. This article will focus on novel design strategies for nanoscale drug delivery systems, based on the unique molecular signatures of myeloid leukemia and EGFR/CD44-positive solid tumors, and the impact of novel discoveries in molecular tumor profiles on future chemotherapeutic protocols.

show abstract

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

Cited by 61 publications

References 29 publications

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)

Polymeric and Lipid Nanoparticles: Which Applications in Pediatrics?

The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors

Contact Info

Product

Resources

About